EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial

Collaboration with AAV-specialist CDMO will support scalable production of EPY201 for focal refractory epilepsy affecting 10 million people LONDON and SAN SEBASTIÁN, Spain, Sept. 9, 2026 /PRNewswire/ -- EpilepsyGTx, a biotechnology company developing gene therapies for refractory...